Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
hematologic neoplasms
MeSH D019337 - hematologic neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009371:
Neoplasms by site
0 Companies
0 Drugs
Success rate
D006402:
Hematologic diseases
33 Companies
3 Drugs
$
Success rate
D019337:
Hematologic neoplasms
1 Company
1 Drug
$
Success rate
D019046:
Bone marrow neoplasms
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
No Data
Clinical Trials
Historical Success Rate
Phase 1
46
%
85/184
Phase 2
18
%
24/132
Phase 3
11
%
3/27
Approved:
1
Overall Success rate:
1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Novartis
Midostaurin
,
Vatalanib
,
AFURESERTIB
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use